Abstract
HIV/AIDS continues to be a significant public health problem. Millions of people worldwide are infected with this virus daily, and thousands die yearly of AIDS-related illnesses. Despite rapid advances in our knowledge about HIV and its mode of transmission, we have been unable to find a cure or prevent new infections. Psychiatric comorbidity is associated with HIV/AIDS: as a risk factor for HIV infection, a comorbidity of HIV infection, sequelae of HIV/AIDS, and a potential mediator for progression to AIDS. In this article, we focus on depression, which is prevalent in HIV/AIDS. We review the evidence associating depression with HIV, the challenges in recognizing depression in HIV-positive individuals, and the psychopharmacologic strategies known to be effective in the treatment of HIV-positive individuals with depression.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
AIDS Epidemic Update: December 2004. Joint United Nations Programme on HIV/AIDS. Geneva: World Health Organization; 2004.
Centers for Disease Control and Prevention: HIV/AIDS: Surveillance Report 2003, vol 15. Centers for Disease Control and Prevention website. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2003:1–46. http://www.cdc.gov./hiv/topics/surveillance/resources/reports. Accessed April 10, 2008.
Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report 1998, vol 10, no 2. Centers for Disease Control and Prevention website. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 1998:1–43. www.cdc.gov./hiv/stats/hasrlink.htm. Accessed April 10, 2008.
US Census Bureau: Census Brief: Women in the United States: a Profile. March 2000. US Census Bureau website. http://www.census.gov/prod/www.abs/populatio.html. Accessed April 10, 2008.
Centers for Disease Control and Prevention. HIV Prevention in the Third Decade. Centers for Disease Control and Prevention website. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2003. http://www.cdc.gov/hiv/resources/reports/hiv3rddecae/index.html. Accessed April 10, 2008.
Anderson RN, Smith BL: Deaths: leading causes for 2001. Natl Vital Stat Rep 2003; 52:32–33, 53–54.
Bing EG, Burnam MA, Longshore D, et al.: Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001, 58:721–728.
Ciesla JA, Roberts JE: Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001, 158:725–730.
Morrison MF, Petitto JM, Ten Have T, et al.: Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry 2002, 159:789–796.
Ickovicks JR, Hamburger ME, Vlahov D, et al.: Mortality, CD4 cell count decline and depressive symptoms among HIV seropositive women. Longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001, 285:1466–1474.
Leserman J, Petitto JM, Gu H, et al.: Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med 2002, 32:1059–1073.
Burack JH, Barrett DC, Stall RD, et al.: Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA 1993, 270:2568–2573.
Evans DL, Leserman J, Perkins DO: Stress-associated reductions of cytotoxic T lymphocytes and natural killer cells in asymptomatic HIV infection. Am J Psychiatry 1995, 152:543–550.
Lyketsos CG, Hoover DR, Guccione M, et al.: Changes in depressive symptoms as AIDS develops. Am J Psychiatry 1996, 153:1430–1437.
Lyketsos CG, Hoover DR, Guccione M, et al.: Depressive symptoms as predictors of medical outcomes in HIV infection. JAMA 1993, 270:2563–2567.
Mayne TJ, Vittinghoff E, Chesney MA: Depressive affect and survival among gay and bisexual men infected with HIV. Arch Intern Med 1996, 156:2233–2238.
Page-Shafer K, Delorenze GN, Satariano WA: Comorbidity and survival in HIV-infected men in the San Francisco Men’s Health Survey. Ann Epidemiol 1996, 6:420–430.
Patterson TL, Shaw WS, Semple SJ, et al.: Relationship of psychosocial factors to HIV disease progression. Ann Behav Med 1996, 18:30–39.
Cruess DG, Evans DL, Repetto MJ, et al.: Prevalence, diagnosis and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry 2003, 54:307–316.
Leserman J: HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry 2003, 54:295–306.
Cook JA, Grey D, Burke-Miller J, et al.: Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-site cohort of HIV-positive women. AIDS Care 2006, 18:93–100.
Evans DL, Charney DS, Lewis L, et al.: Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005, 58:175–189.
Evans DL, Staab JP, Petitto JM, et al.: Depression in the medical setting: biopsychological interactions and treatment considerations. J Clin Psychiatry 1999, 60:40–55.
Evans DL, Charney DS: Mood disorders and medical illness: a major public health problem. Biol Psychiatry 2003, 54:177–180.
Starace F, Ammassari A, Trotta P, et al.: Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002, 31(Suppl 3):S136–S139.
Kissane D, Clarke DM, Street AF: Demoralization syndrome: a relevant psychiatric diagnosis for palliative care. J Palliat Care 2001, 17:12–21.
Schade CP, Jones ER, Witten BJ: A ten year review of the validity and clinical utility of depression screening. Psychiatr Serv 1998, 49:55–61.
Lyketsos CG, Triesman GJ: Mood disorders in HIV infection. Psychiatr Ann 2001, 31:45–50.
Triesman GJ, Angelino AF, Hutton HE: Psychiatric issues in the management of patients with HIV infection. JAMA 2001, 286:2857–2864.
Elliot AJ, Russo J, Roy-Burne PP: The effect of changes in depression on health related quality of life (HRQol) in HIV infection. Gen Hosp Psychiatry 2002, 24:43–47.
Rabkin JG, Wagner GJ, Rabkin R: Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry 1999, 156:101–107.
Grassi B, Gambini O, Garghentini, et al.: Efficacy of paroxetine for the treatment of depression in the context of HIV infection. Pharmacopsychiatry 1997, 30:70–71.
Ferrando SJ, Goldman JD, Charness WE: Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS: improvements in affective and somatic symptoms. Gen Hosp Psychiatry 1997, 19:89–97.
Ferrando SJ, Rabkin JG, de Moore GM, et al.: Antidepressant treatment for depression in HIV-seropositive women. J Clin Psychiatry 1999, 60:741–746.
Currier MB, Molina G, Kato M: Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: a prospective study. Psychosomatics 2004, 45:210–216.
Schwartz JA, McDaniel JS: Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: a pilot study. Depress Anxiety 1999, 9:70–74.
Robinson MJ, Qaqish RB: Practical psychopharmacology in HIV-1 and acquired immunodeficiency syndrome. Psychiatr Clin North Am 2000, 25:149–175.
Himelhoch S, Medoff DR: Efficacy of antidepressant medication among HIV positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STDS 2005, 19:813–822.
Rabkin JG, Rabkin R, Harrison W, et al.: Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry 1999, 156:367–372.
Elliot AJ, Uldall KK, Bergman K: Randomized placebocontrolled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry 1998, 155:367–372.
Markowitz JC, Kocsis JH, Fishman B, et al.: Treatment of depressive symptoms in human immunodeficiency virus positive patients. Arch Gen Psychiatry 1998, 55:452–457.
Elliot AJ, Russo J, Bergam K, et al.: Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. J Clin Psychiatry 1999, 60:226–231.
Elliot AJ, Roy-Byrne PP: Mirtazapine for depression in patients with human immunodeficiency virus [letter]. J Clin Psychopharmacol 2000, 20:265–267.
Currier MB, Molina G, Kato M: A prospective trial of sustained release bupropion for depression in HIV-seropositive and AIDS patients. Psychosomatics 2003, 44:120–125.
Wagner GJ, Rabkin JG, Rabkin R: Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. J Psychosom Res 1997, 42:407–411.
Wagner GJ, Rabkin R: Effects of dextroamphetamine on depression and fatigue in men with HIV: a double blind, placebo controlled trial. J Clin Psychiatry 2000, 62:436–440.
Brietbart W, Rosenfeld B, Kaim M, et al.: A randomized, double-blind, placebo controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001, 161:411–420.
Rabkin JG, Wagner GJ, Rabkin R: A double-blind, placebo controlled trial of testosterone for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000, 57:141–147.
Rabkin JG, Ferrando SJ, Wagner GJ: DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters. Psychoneuroendocrinology 2000, 25:53–68.
Piscitelli SC, Burstein AH, Chaitt D: Indinavir concentrations and St. John’s wort. Lancet 2000, 355:547–548.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Benton, T.D. Depression and HIV/AIDS. Curr Psychiatry Rep 10, 280–285 (2008). https://doi.org/10.1007/s11920-008-0045-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11920-008-0045-y